Market Place
Sourcing Support
Rakovina Therapeutics to Highlight PARP1/2 Inhibitors at EORTC
25 Oct 2024 //
GLOBENEWSWIRE
Rakovina Announces Initial Drug Candidates from AI Platform
23 Oct 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics and Variational AI Announce Drug Discovery Pact
17 Sep 2024 //
GLOBENEWSWIRE
Rakovina Partners For AI-Driven Cancer Target Selection
17 Sep 2024 //
FIERCE BIOTECH
Rakovina Therapeutics Announces 2024 Q2 Financial Results
30 Aug 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Closes Oversubscribed Private Placement
26 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
22 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Second Upsizing of Private Placement
19 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Oversubscribed Private Placement
20 Jun 2024 //
GLOBENEWSWIRE
Rakovina Provides Q1 2024 Financials And Business Update
30 May 2024 //
GLOBENEWSWIRE
Rakovina Debenture Interest Payment: Partial Shares Elected By Debentureholders
24 May 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
23 May 2024 //
GLOBENEWSWIRE
Rakovina Expands AI Research Collaborations
08 May 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics 2023 Results, Corporate Update
26 Apr 2024 //
GLOBENEWSWIRE
Rakovina at AACR Annual Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
01 Apr 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Strategic Pivot to AI
27 Mar 2024 //
GLOBENEWSWIRE
Rakovina Welcomes Prof. Artem Cherkasov to Company™s Scientific Advisory Board
27 Nov 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results
27 Nov 2023 //
GLOBENEWSWIRE
Rakovina Announces Appointment of New Scientific Advisory Board Member
20 Nov 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q2 2023 FYR and Provides Corporate Update
29 Aug 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
28 Jun 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results
31 May 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Closing of $1.5M Convertible Debenture Financing
29 May 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible
01 May 2023 //
GLOBENEWSWIRE
Rakovina Inc. Announces Enhanced Liquidity and Investor Awareness Programs
30 Mar 2023 //
GLOBENEWSWIRE
Rakovina Receives Funding to Accelerate Development of Novel Cancer Therapies
22 Mar 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Plan to Apply to Extend Warrant Expiry Dates
10 Mar 2023 //
GLOBENEWSWIRE
Rakovina Announces Presentation at the 6th Annual DDR-inhibitors Summit
26 Jan 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present at the Emerging Growth Conference in November
23 Nov 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results
17 Nov 2022 //
GLOBENEWSWIRE
Rakovina Announces Publication Activity Novel Bi-functional PARP-HDAC
14 Nov 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Data Presentation at EORTC-NCI-AACR
31 Oct 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations
28 Sep 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q2 2022 FY Result
11 Aug 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Results from Annual General Meeting
23 Jun 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Q1 2022 Financial Results
26 May 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series
11 May 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces 2021 Financial Results
27 Apr 2022 //
GLOBENEWSWIRE
Rakovina and its Preclinical Data on Anticancer Activity of kt-4000 Series
14 Apr 2022 //
GLOBENEWSWIRE
Rakovina Presents Data on Potential Broad Anticancer Activity of kt-4000 Series
12 Apr 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present Abstract at the 2022 AACR
30 Mar 2022 //
GLOBENEWSWIRE
Rakovina Tx to Present Abstract at the 2022 AACR
09 Mar 2022 //
GLOBENEWSWIRE
Rakovina`s President to Join Expert Panel at 5th Annual Inhibitors Summit
25 Jan 2022 //
GLOBENEWSWIRE
Rakovina Announces Non-dilutive Financial Contributions Anti-cancer Agents
21 Dec 2021 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results
23 Nov 2021 //
GLOBENEWSWIRE
Rakovina Partners with St. Baldrick’s Foundation to Research and Develop
16 Nov 2021 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research
21 Oct 2021 //
GLOBENEWSWIRE
Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtua
12 Oct 2021 //
GLOBENEWSWIRE
